Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study

Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study

Purpose of the article: Baricitinib, a JAK 1/2 inhibitor, is approved for treating severe alopecia areata (AA). This study aimed to evaluate the long-term effectiveness and safety of baricitinib in a real-world setting over 52 weeks.Materials and methods: This multicenter retrospective study include...

Full description

Saved in:
Bibliographic Details
Main Authors: Carlo A. Vignoli, Luigi Gargiulo, Luciano Ibba, Anna Balato, Mauro Barbareschi, Stefania Barruscotti, Giulia Bazzacco, Francesco Bellinato, Vittoria G. Bianchi, Valeria Boccaletti, Raffaele D. Caposiena Caro, Silvia M. Ferrucci, Alessandro Fraghì, Elisabetta Fulgione, Giuseppe Gallo, Paolo Gisondi, Isotta Giunipero di Corteranzo, Piergiorgio Malagoli, Angelo V. Marzano, Santo R. Mercuri, Diego Orsini, Pietro Quaglino, Simone Ribero, Antonio Costanzo, Alessandra Narcisi
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Journal of Dermatological Treatment
Subjects:
Alopecia areata
baricitinib
ClinRO
JAK inhibitors
SALT
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2024.2444494
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of the article: Baricitinib, a JAK 1/2 inhibitor, is approved for treating severe alopecia areata (AA). This study aimed to evaluate the long-term effectiveness and safety of baricitinib in a real-world setting over 52 weeks.Materials and methods: This multicenter retrospective study included 96 adult patients diagnosed with severe AA from 11 Italian Dermatology Units. All patients received 4 mg of baricitinib daily. Effectiveness was assessed using the Severity of Alopecia Tool (SALT) score, with the primary endpoint defined as achieving a SALT score ≤ 20 at week 52. Secondary endpoints included achieving a Clinician-Reported Outcome (ClinRO) score of 0 or 1 for eyebrow (ClinRO EB) and eyelash hair loss (ClinRO EL), with a ≥ 2-point improvement from baseline.Results: After 52 weeks, 61.5% of patients achieved a SALT score ≤ 20. Additionally, 67.6% and 69.7% of patients attained ClinRO EB and ClinRO EL scores of 0 or 1, respectively, with a ≥ 2-point improvement. No significant adverse safety events were reported during the study.Conclusions: The study confirms the long-term effectiveness and safety of baricitinib for severe AA in a real-world setting. These findings align with clinical trial results and reinforce baricitinib’s role as a viable treatment option for severe AA.
ISSN:0954-6634
1471-1753

Similar Items